New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

- Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years


-...

Related Keywords

United States ,Delaware ,Amsterdam ,Noord Holland ,Netherlands ,Berlin ,Germany ,American ,Jim Lee ,Albert Wolkerstorfer ,European Academy Of Dermatology ,Exchange Commission ,Netherlands Institute For Pigment Disorders ,American Academy Of Dermatology ,Group Vice ,Us Food Drug Administration ,Department Of Dermatology ,University Of Amsterdam ,Late Breaking News ,European Academy ,Group Vice President ,Annual Meeting ,Netherlands Institute ,Pigment Disorders ,Drug Administration ,Full Prescribing Information ,Boxed Warning ,Medication Guide ,Markets ,